Blue Horizon International

What Blue Horizon International does

Blue Horizon International (BHI) is a global healthcare company founded in 2009 and headquartered in Hackensack, New Jersey, that delivers adult and pediatric stem cell-based therapies through a network of international treatment facilities. Its clinical portfolio spans human cord blood stem cells, Wharton's Jelly-derived mesenchymal stem cells (MSCs), adipose-derived stromal vascular fraction (SVF) cell therapy, and a cancer immunotherapy platform that uses expanded dendritic and killer T-cells, with indications covering chronic inflammation, osteoarthritis, spinal cord injury, stroke, and musculoskeletal disorders. The FDA has authorized progression along the Investigational New Drug (IND) pathway for an acute ischemic stroke study (NCT03735277). Operationally, BHI runs treatment sites in Slovakia (Malacky Hospital, licensed by the Slovak Ministry of Health) and Jamaica (Montego Bay and Ocho Rios), operates a US clinical-trial entry point in Houston, Texas via its Delaware corporation BHI Therapeutic Sciences (BHITS), and partners with Wuhan University's Department of Medicine and Biochemistry Institute along with Wuhan Hongqiao Brain Hospital in China. The company has reported more than 4,000 stem cell therapies performed cumulatively across its facilities.

BHI generates revenue primarily through direct patient payments for stem cell therapies at its international facilities, supplemented by consumer-product revenue from its Alpha Blu cosmetic skincare line (built on stem-cell-derived conditioned media containing 32 human cytokines and growth factors) and revenue from its BHI Rejuve hormone optimization program. Distribution occurs through direct treatment at international facilities, an owned e-commerce channel for Alpha Blu, physician and institutional referrals cultivated via conference participation (AAOS, A4M, World Economic Forum, World Stem Cells Congress), and a multi-channel brand-building effort that includes documentary films, an athlete ambassador program, and the Blue Horizon Charitable Foundation's humanitarian work. Its customer base is composed of individual patients seeking regenerative-medicine alternatives to conventional treatment for chronic conditions, plus a small number of high-profile professional athletes serving as brand ambassadors; the company has named entrepreneur-led leadership (founder/CMO Dr. Brian Mehling and CEO Doreen Santora, RN/MHA) and a Scientific Advisory Board that includes faculty from Wuhan University, USC Keck, University of Pennsylvania, and Mount Sinai.

Name

Blue Horizon International

Legal name

Blue Horizon International, LLC

Website

https://bluehorizoninternational.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Blue Horizon International is a Hackensack-based regenerative medicine company delivering adult and pediatric stem cell therapies — cord blood, Wharton's Jelly MSCs, and adipose-derived SVF — through international facilities in Slovakia, Jamaica, China, and Texas, serving patients with chronic, orthopedic, and neurological conditions.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Blood and Organ Banks (621991), Scientific Research and Development Services (5417), Other Ambulatory Health Care Services (6219)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

Keywords

• Stem cell therapy
• Regenerative medicine
• Cellular therapy
• Orthopedic surgery
• Hormone optimization

Headquarters

HQ city

Hackensack

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Stem Cell Therapy Treatments: Direct patient payments for stem cell therapies at international treatment facilities. Services include treatment for chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders, osteoarthritis, and other medical conditions.
2. Cosmetic Products: Sale of Alpha Blu cosmetic skincare products developed from stem cell research containing conditioned media with human cytokines and growth factors.
3. BHI Rejuve Hormone Optimization: Hormone optimization programs offered through BHI Rejuve division.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Blue Horizon International is a healthcare company that delivers adult and pediatric stem cell-based regenerative therapies to patients at international facilities in Slovakia, Jamaica, the US, and through partnerships in China. Treatments utilize ethically sourced umbilical cord blood stem cells, Wharton's Jelly mesenchymal stem cells, and stromal vascular fraction (SVF) cells, addressing conditions such as chronic inflammation, stroke, spinal cord injury, osteoarthritis, and musculoskeletal disorders. The company also sells the Alpha Blu conditioned-media skincare line and offers BHI Rejuve hormone optimization programs.

Product overview

Blue Horizon International is a global healthcare company operating through multiple divisions: Blue Horizon Stem Cells (core therapy division with 4,000+ therapies performed), BHI Therapeutic Sciences (biotechnology R&D with 60 FDA protocols), Mehling Orthopedics (orthopedic surgery), plus sub-brands BHI Rejuve (hormone optimization), Alpha Blu Skin Care (stem cell-derived cosmetics), and Blue Horizon Charitable Foundation (philanthropy). The portfolio spans adult and pediatric stem cell therapies using cord blood, Wharton's Jelly MSCs, and adipose-derived SVF cells; orthopedic treatments; anti-aging wellness; and educational/documentary content. The company operates internationally with facilities in Slovakia, Jamaica, and the U.S.

Differentiator

Problem solved

Functional benefit

Brands

• Blue Horizon Stem Cells: A division providing stem cell therapy and research to achieve health benefits.
• BHI Rejuve
• Alpha Blu
• Blue Horizon Charitable Foundation

Products and services

• Blue Horizon Stem Cells A therapy division delivering stem cell treatments for conditions including chronic inflammation, stroke, spinal cord injury, osteoarthritis, and other musculoskeletal and neurological disorders. Treatment protocols use mesenchymal stem cells (MSCs), Wharton's Jelly-derived MSCs, stromal vascular fraction (SVF) cells, and cord blood mononuclear cells delivered through intravenous, intrathecal, and intra-articular routes. Intended for self-paying adult and pediatric patients seeking regenerative medicine alternatives internationally.
• Alpha Blu Skin Care A skincare product line developed from Blue Horizon's stem cell research, featuring conditioned media containing 32 human cytokines and growth factors obtained from human stem cell cultures. Sold to consumers through the company's own sales channels and at conferences.
• BHI Rejuve A hormone optimization program offered as a division of Blue Horizon International, focused on anti-aging and wellness treatments for individual patients.
• Mehling Orthopedics An orthopedic surgery practice specializing in regenerative medicine. Performs complex orthopedic fracture surgeries including high velocity fractures, open fractures, and complex pelvic ring injuries, delivered by American Board of Orthopedic Surgery-certified surgeons.

Quantifiable outcome

• 84.9% of patients showed improvement in pain levels 12 months after SVF cell therapy for osteoarthritis
• +4 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• Wuhan University (Biochemistry Institute)coreStrategic or Co-development PartnerBHI is the only treatment provider approved and associated with The Wuhan University Department of Medicine and The Biochemistry Institute of Wuhan University. This partnership provides access to Chinese research institutions and treatment facilities including Wuhan Hongqiao Brain Hospital.
• Ministry of Health of the Slovak RepubliccoreStrategic or Co-development PartnerFull licensing by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital near Bratislava, Slovakia.
• BHIAG (Swiss Holding Company)coreStrategic or Co-development PartnerBHIAG is a Swiss holding company that has treated over 577 research subjects with various conditions. All intellectual property generated by BHIAG's overseas entities is exclusively licensed to BHITS for domestic US operations.
• Mehling OrthopedicsmajorStrategic or Co-development PartnerOrthopedic trauma surgery practice led by Dr. Brian Mehling. Performs complex orthopedic fracture surgeries including high velocity fractures, open fractures, and complex pelvic ring injuries. All doctors certified by the American Board of Orthopedic Surgeons.
• Wuhan Hongqiao Brain HospitalmajorStrategic or Co-development PartnerChinese hospital partnership for stem cell treatment of neurological conditions including spinal cord injury. Subjects treated between March 2009 and March 2012 as part of BHI research studies.
• Malacky Hospital (Slovakia)coreStrategic or Co-development PartnerSlovakia's first and only treatment facility for cellular and regenerative medicine. Celebrated treatment of its 100th patient milestone. Licensed by Ministry of Health for cord blood, bone marrow and adipose stem cell treatments.
• American Academy of Orthopaedic Surgeons (AAOS)majorGTM or Marketing PartnerBHI Therapeutic Sciences and Mehling Orthopedics attend and exhibit at AAOS Annual Meetings. Dr. Mehling presents research and exchanges ideas with orthopedic surgeon colleagues at the world's largest orthopaedic meeting.
• World Economic Forum (WEF)majorGTM or Marketing PartnerDr. Brian Mehling regularly attends WEF Annual Meetings in Davos, Switzerland as a participant. BHI is listed as a WEF member organization.
• Joint Commission International (JCI)majorStrategic or Co-development PartnerBHI management has demonstrated superior ability to exceed JCI standards and aims to establish JCI disease-specific accredited programs in each market they enter, with pathways for eventual JCI and Magnet Nursing credentialing.
• Industrial Motion Pictures (IMP)minorStrategic or Co-development PartnerFilm production company founded by Dr. Brian Mehling that produces documentary films about stem cell therapy and humanitarian causes including 'A Smile for Bow' and 'Stem Cells: The Next Frontier'.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Celltex Therapeutics: Houston-based company that isolates, banks, and provides autologous mesenchymal stem cell therapies, closely mirroring BHI's SVF/MSC autologous-to-allogeneic model and US footprint. Operates in the same regulatory gray zone between FDA IND pathways and cash-pay clinical use.
• Regenexx: Network of US clinics specializing in image-guided, autologous stem cell and platelet treatments for orthopedic conditions including osteoarthritis and joint injury. Highly comparable to BHI's SVF-for-osteoarthritis and Mehling Orthopedics offerings.
• Stem Cell Institute (MediStem Panama): Panama-based clinic offering adult stem cell therapies for orthopedic, neurological, and autoimmune conditions on a medical-tourism basis. Directly comparable business model to BHI's offshore cash-pay treatment network in Slovakia, Jamaica, and China.
• BioXcellerator: International stem cell clinic treating orthopedic, neurological, and autoimmune conditions with cultured MSCs and Wharton Jelly-derived cells. Closely comparable to BHI's Wharton's Jelly MSC protocols and medical-tourism delivery model.
• Swiss Medica: European stem cell therapy provider operating across Switzerland and Serbia, treating chronic and degenerative diseases on a medical-tourism basis. Comparable to BHI's Malacky Hospital/Slovakia platform in scope, geography, and patient-acquisition approach.
• AgeRejuvenation: US clinic chain offering autologous stem cell and exosome therapies for orthopedic, wellness, and anti-aging indications. Comparable to BHI Rejuve and Blue Horizon Stem Cells on the cash-pay regenerative medicine side.

Broad incumbents

• Celularity Inc. Publicly traded cellular medicine company developing placental-derived allogeneic cell therapies including for stroke and orthopedic indications. Comparable at the indication level to BHI's cord-blood stroke IND and SVF osteoarthritis work, but operates at significantly larger scale and with FDA-grade development infrastructure.
• Vericel Corporation: Commercial-stage cell therapy company with FDA-approved autologous cartilage repair (MACI) and burn products. Comparable as a benchmark for what an FDA-approved, commercial-scale orthopedic cell therapy business looks like, against which BHI's IND-stage pipeline can be sized.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/groups/2138324746251642
• Xx.com/BlueHorizonIntl

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blue Horizon International